{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:23Z","timestamp":1791223763746,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"DOI":"10.1093\/cid\/ciu397","type":"journal-article","created":{"date-parts":[[2014,5,31]],"date-time":"2014-05-31T00:18:21Z","timestamp":1401495501000},"page":"676-681","source":"Crossref","is-referenced-by-count":353,"title":["Lyme Disease Testing by Large Commercial Laboratories in the United States"],"prefix":"10.1093","volume":"59","author":[{"given":"Alison F.","family":"Hinckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta P.","family":"Connally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Kemperman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,5,30]]},"reference":[{"key":"key\n\t\t\t\t20170522155242_CIU397C1","first-page":"26","article-title":"Summary of notifiable diseases, United States, 2008","volume":"57","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522155242_CIU397C2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-86-6-685","article-title":"Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum","volume":"86","year":"1977","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-99-1-76","article-title":"The early clinical manifestations of Lyme disease","volume":"99","year":"1983","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.7326\/0003-4819-107-5-725","article-title":"The clinical evolution of Lyme arthritis","volume":"107","year":"1987","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.34.1.1-9.1996","article-title":"Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans","volume":"34","year":"1996","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1212\/WNL.39.6.753","article-title":"Lyme neuroborreliosis: central nervous system manifestations","volume":"39","year":"1989","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170522155242_CIU397C8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJM199011223232102","article-title":"Chronic neurologic manifestations of Lyme disease","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archneur.1989.00520430086023","article-title":"Central nervous system manifestations of Lyme disease","volume":"46","year":"1989","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM198908313210906","article-title":"Lyme disease","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.1993.03500140064037","article-title":"The overdiagnosis of Lyme disease","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170522155242_CIU397C12","first-page":"590","article-title":"Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease","volume":"44","author":"Centers for Disease Control and Prevention","year":"1995","journal-title":"Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522155242_CIU397C13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/CMR.18.3.484-509.2005","article-title":"Diagnosis of Lyme borreliosis","volume":"18","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20170522155242_CIU397C14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0025-7125(03)00089-0","article-title":"Laboratory testing for suspected Lyme disease","volume":"86","year":"2002","journal-title":"Med Clin North Am"},{"key":"key\n\t\t\t\t20170522155242_CIU397C15","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1128\/JCM.01853-13","article-title":"Comparative cost effectiveness of two-tiered testing strategies for the serodiagnosis of Lyme disease with noncutaneous manifestations","volume":"51","year":"2013","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C16","first-page":"34","article-title":"Summary of notifiable diseases, United States, 2009","volume":"58","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522155242_CIU397C17","first-page":"28","article-title":"Summary of notifiable diseases, United States, 2007","volume":"56","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170522155242_CIU397C18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1086\/374395","article-title":"Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates","volume":"187","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/648674","article-title":"2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/infdis\/167.2.392","article-title":"Western blotting in the serodiagnosis of Lyme disease","volume":"167","year":"1993","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/JCM.33.2.419-427.1995","article-title":"Immunoblot interpretation criteria for serodiagnosis of early Lyme disease","volume":"33","year":"1995","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00129492-200409000-00031","article-title":"The VlsE(IR6) peptide ELISA in the serodiagnosis of Lyme facial paralysis","volume":"25","year":"2004","journal-title":"Otol Neurotol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.diagmicrobio.2012.09.003","article-title":"Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease","volume":"75","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/infdis\/174.2.346","article-title":"Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting","volume":"174","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1370\/afm.117","article-title":"Appropriateness of Lyme disease serologic testing","volume":"2","year":"2004","journal-title":"Ann Fam Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C26","volume-title":"Projected annual market for rapid direct tests. Rapid testing for infectious diseases: competitive advantage in a turbulent market","author":"Migliara\/Kaplan Associates","year":"1993"},{"key":"key\n\t\t\t\t20170522155242_CIU397C27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/517311","article-title":"Utilization and cost of serologic tests for Lyme disease in Maryland","volume":"176","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/cid\/cir464","article-title":"Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay","volume":"53","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00124784-199623000-00017","article-title":"Underreporting of Lyme disease by Connecticut physicians, 1992","volume":"2","year":"1996","journal-title":"J Public Health Manag Pract"},{"key":"key\n\t\t\t\t20170522155242_CIU397C30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/aje\/155.12.1120","article-title":"Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort","volume":"155","year":"2002","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/oxfordjournals.aje.a009462","article-title":"Emergence of Lyme disease in Hunterdon County, New Jersey, 1993: a case-control study of risk factors and evaluation of reporting patterns","volume":"147","year":"1998","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C32","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJM199805283382216","article-title":"Underreporting of Lyme disease","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/JCM.32.6.1519-1525.1994","article-title":"Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis","volume":"32","year":"1994","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170522155242_CIU397C34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7326\/0003-4819-156-2-201201170-00011","article-title":"Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care","volume":"156","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/314663","article-title":"Evaluation of two-test serodiagnostic method for early Lyme disease in clinical practice","volume":"179","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jama.279.3.206","article-title":"Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy","volume":"279","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170522155242_CIU397C37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7326\/0003-4819-127-12-199712150-00011","article-title":"Laboratory evaluation in the diagnosis of Lyme disease","volume":"127","year":"1997","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170522155242_CIU397C38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1086\/314651","article-title":"A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease","volume":"179","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522155242_CIU397C39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/171.2.356","article-title":"Biliary complications in the treatment of unsubstantiated Lyme disease","volume":"171","year":"1995","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:03:42Z","timestamp":1597921422000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciu397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,30]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,30]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu397","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,30]]}}}